Literature DB >> 18252791

Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.

Polyzois Makras1, Neveen A T Hamdy, Sarina G Kant, Socrates E Papapoulos.   

Abstract

CONTEXT: X-linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia and growth retardation. Early diagnosis and treatment improve growth.
OBJECTIVE: Our objective was to describe long-term observations of a family with XLH due to a novel mutation of the PHEX gene with unusual clinical features, including normal growth. PATIENTS: The mother and her two sons were followed in the same institution for nearly 30 yr.
RESULTS: The mother had hypophosphatemia and normal height (Z score, -0.6) without ever receiving any treatment. Her two sons achieved final heights of 183.7 cm (Z score, -0.01) and 182.7 cm (Z score, -0.18), respectively, despite late initiation of treatment with phosphate and low serum phosphate levels. In addition, they had reversible proximal myopathy that took about 7 yr to resolve in one of them. Direct sequencing of the PHEX gene revealed a new splice site mutation in intron 4 of the gene (IVS4+6T-->C) resulting in skipping of exon 4.
CONCLUSIONS: Three members of a family with XLH due to a novel mutation of the PHEX gene had a normal growth pattern despite late diagnosis and treatment of the two boys and no treatment at all of their mother. The pathophysiological basis of this phenotype-genotype association warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252791     DOI: 10.1210/jc.2007-1296

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

Review 2.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Phosphate regulates embryonic endochondral bone development.

Authors:  Alena A Zalutskaya; Megan K Cox; Marie B Demay
Journal:  J Cell Biochem       Date:  2009-10-15       Impact factor: 4.429

Review 4.  Hypophosphatemia and growth.

Authors:  Fernando Santos; Rocío Fuente; Natalia Mejia; Laura Mantecon; Helena Gil-Peña; Flor A Ordoñez
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

5.  Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability.

Authors:  Tjin-Shing Jap; Chih-Yang Chiu; Dau-Ming Niu; Michael A Levine
Journal:  Calcif Tissue Int       Date:  2011-02-04       Impact factor: 4.333

6.  Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: identification as an allele of 'Hyp'.

Authors:  Kenji Moriyama; Atsuko Hanai; Kazuyuki Mekada; Atsushi Yoshiki; Katsueki Ogiwara; Atsushi Kimura; Takayuki Takahashi
Journal:  J Biomed Sci       Date:  2011-08-20       Impact factor: 8.410

Review 7.  Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.

Authors:  Claudia Maria Jurca; Oana Iuhas; Kinga Kozma; Codruta Diana Petchesi; Dana Carmen Zaha; Marius Bembea; Sanziana Jurca; Corina Paul; Alexandru Daniel Jurca
Journal:  Genes (Basel)       Date:  2022-08-04       Impact factor: 4.141

8.  PHEXL222P Mutation Increases Phex Expression in a New ENU Mouse Model for XLH Disease.

Authors:  Carole El Hakam; Alexis Parenté; Fabienne Baraige; Laetitia Magnol; Lionel Forestier; Florent Di Meo; Véronique Blanquet
Journal:  Genes (Basel)       Date:  2022-07-28       Impact factor: 4.141

Review 9.  Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.

Authors:  Rocío Fuente; María García-Bengoa; Ángela Fernández-Iglesias; Helena Gil-Peña; Fernando Santos; José Manuel López
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.